Jumpcode Genomics
JUMPCODE's CRISPR-mediated rRNA depletion kits remove nucleic acids from sequencing workflows to improve sensitivity and performance.
Funding reportedLast round: Series B
Follow Jumpcode Genomics and see its new rounds in your feed.Start following
What company datasets say Jumpcode Genomics raised
Funding, as reported
Reported in all23.5Min the source's currency
Rounds2
Last roundSeries B
Last round dateJan 2021
Investors listed3
Founders and team
From Jumpcode Genomics's own website: 1 on the team.
- Mike SalterCEO/President
AdvisersCourt Turner
On a portfolio page
Investors who name them
Each firm lists Jumpcode Genomics on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.
Biotechnology in the same market
Startups like it
Is this your company?
Add your raise, your deck and your story, and put Jumpcode Genomics in front of investors. Or tell us what we have wrong.